Summary
Febrile Neutropenia is a relevant factor for mortality after chemotherapy. Dependent upon factors like duration of neutropenia (≥7 d means high-risk situation), patient- and disease specific criteria e.g. defined in the MASCC score (Multinational Association of Supportive Care in Cancer) the individual risk for the patient for the need of being hospitalized can be estimated. Antimicrobial therapy has to be started immediately, to avoid high mortality. Empiric or calculated antiinfective therapy includes broadspectrum-lactam antibiotics in first-line. After 72 to 96 h of treatment, when the patients are still febrile and clinically not improving, an empiric switch of the antibiotic treatment can be considered, e.g. closing the gaps in the gram-positive spectrum. In this situation high risk patients also should receive an antifungal agent with activity against aspergillus spp. Strategies to prevent infection in neutropenia are antiinfective prophylaxis or the use of G-CSF (granulocyte-colony stimulating factor). Antibiotic prophylaxis might help to prevent infections and to improve outcome esp. for high risk patients. Antifungal prophylaxis including Aspergillus species is recommended in the situation of induction therapy for acute myelogenic leukemia. Patients, expecting a phase of prolonged neutropenia with a history of mold infection should receive a secondary antifungal prophylaxis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of internal medicine, 64(2): 328–40, 1966
Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis, 32(3): 381–90, 2001
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 52(4): e56–93, 2010
Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol, 24(25): 4129–34, 2006
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 18(16): 3038–51, 2000
Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis, 39(Suppl. 1): S32–7, 2004
Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. International journal of antimicrobial agents, 30(Suppl 1): S51–9, 2007
Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis, 29(3): 490–4, 1999
Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis, 36(2): 149–58, 2003
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6): 1589–96, 2006
Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis, 43(4): 447–59, 2006
Cherif H, Bjorkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scandinavian journal of infectious diseases, 36(8): 593–600, 2004
Raad, II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer, 98(5): 1039–47, 2003
Wang FD, Liu CY, Hsu HC, et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy, 45(5): 370–9, 1999
Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother, 42(4): 511–8, 1998
Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol, 18(21): 3690–8, 2000
Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol, 79(3): 152–7, 2000
Lindblad R, Rodjer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis, 30(3): 237–43, 1998
Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol, 76(2): 73–80, 1998
Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res, 3(7): 324–30, 1998
Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol, 39(6): 2206–12, 2001
Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis, 7(5): 338–48, 2007
Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev, (3): CD003038, 2003
Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. The Journal of antimicrobial chemotherapy, 55(4): 436–44, 2005
Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis, 37(3): 382–9, 2003
Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol, 26(4): 606–11, 2008
Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis, 41(9): 1242–50, 2005
Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis, 42(4): 533–40, 2006
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol, 25(21): 3158–67, 2007
Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med, 121(7): 492–501, 1994
Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst, 93(1): 31–8, 2001
Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med, 142(12 Pt 1): 979–95, 2005
Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med, 353(10): 977–87, 2005
Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24(2): 111–8, 2005
Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother, 50(6): 2192–6, 2006
Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med, 353(10): 988–98, 2005
Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol, 117(2): 259–64, 2002
Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med, 100(3): 345–51, 1984
Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol, 27(23): 3849–54, 2009
Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica, 91(8): 1068–75, 2006
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med, 356(4): 348–59, 2007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weissinger, F., Heinz, W. Prevention and treatment of febrile neutropenia. memo 5, 30–34 (2012). https://doi.org/10.1007/s12254-012-0335-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-012-0335-2